<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04603066</url>
  </required_header>
  <id_info>
    <org_study_id>202008183</org_study_id>
    <nct_id>NCT04603066</nct_id>
  </id_info>
  <brief_title>Tariquidar-ondansetron Combination in Neuropathic Pain</brief_title>
  <official_title>Administration of Ondansetron With P-glycoprotein Inhibitor Tariquidar in Patients With Neuropathic Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, randomized, double-blind, placebo controlled, cross-over proof of concept study.&#xD;
&#xD;
      To determine the pharmacokinetics and tolerability of co-administration of 5-HT3R antagonist&#xD;
      ondansetron with a P-glycoprotein inhibitor tariquidar, in patients with neuropathic pain.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators hypothesize that co-administration of a 5-HT3 receptor antagonist&#xD;
      ondansetron (single 16mg dose) with p-glycoprotein inhibitor tariquidar (single 4mg/kg dose)&#xD;
      vs placebo in a cross-over prospective randomized study, will:&#xD;
&#xD;
        1. Be tolerable in patients with neuropathic pain.&#xD;
&#xD;
        2. Increase the cerebrospinal fluid (CSF) to plasma ratio of ondansetron after intravenous&#xD;
           administration, compare to ondansetron alone&#xD;
&#xD;
        3. Result in a greater reduction in pain intensity than with ondansetron alone.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 31, 2021</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Prospective, randomized, double blind, crossover study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concertation-time Profile of Ondansetron in Plasma</measure>
    <time_frame>up to 8 weeks following consent</time_frame>
    <description>Venous blood sampling for plasma concentrations of ondansetron will be obtained: at 0, 15, 30, 60, 90, 120, 180, and 240 minutes from the beginning of ondansetron infusion, and compared between the two sessions (with placebo vs tariquidar)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cerebrospinal Fluid to Plasma Concentration Ratio of Ondansetron</measure>
    <time_frame>up to 8 weeks following consent</time_frame>
    <description>Cerebrospinal fluid to plasma concentration ratio of ondansetron, compared between the two sessions, with placebo vs tariquidar</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cerebrospinal Fluid Penetration of Ondansetron - Area Under the Curve (AUC)</measure>
    <time_frame>up to 8 weeks following consent</time_frame>
    <description>Cerebrospinal fluid penetration of intravenous ondansetron will be determined as AUCCSF0-∞ of ondansetron, and compared between the two sessions, with placebo vs tariquidar</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Pain Intensity</measure>
    <time_frame>up to 8 weeks following consent</time_frame>
    <description>Change in spontaneous pain intensity (measured on 0-10 numerical rating scale; 0=no pain, 10=worst imaginable pain) from baseline to 60-120 minutes after ondansetron IV infusion, compared between two sessions with and without tariquidar.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conditioned Pain Modulation (CPM) Magnitude (ΔCPM)</measure>
    <time_frame>up to 8 weeks following consent</time_frame>
    <description>The difference between self-report intensity of pain (0-100 scale) as a response to a standard contact heat stimulus, compared to the same experiment performed with ice-water conditioning applied to the contralateral extremity. A larger negative value of CPM represents more efficient pain modulation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between CPM Magnitude (ΔCPM) and Change in Pain Intensity</measure>
    <time_frame>up to 8 weeks following consent</time_frame>
    <description>The association between baseline Conditioned Pain Modulation (CPM) magnitude (ΔCPM) and the % pain reduction from baseline will be determined by bivariate regression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Neuropathic Pain Symptom Score</measure>
    <time_frame>up to 8 weeks following consent</time_frame>
    <description>Changes in Neuropathic Pain Symptom Inventory (NPSI) total score and sub-scores (burning pain, paroxysmal pain, paresthesia/dysesthesia score) will be compared between treatment sessions. Each subscore is scored on a 0-10 scale: 0=no symptom, 10=worst imaginable symptom</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Neuropathic Pain</condition>
  <arm_group>
    <arm_group_label>Ondansetron + Tariquidar</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ondansetron + Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron 16 mg with Tariquidar</intervention_name>
    <description>In randomized order, each participant will receive two IV infusions of ondansetron, 3 weeks apart; one with placebo (D5W), and one with tariquidar (4mg/kg dose in D5W) administered IV over 60 minutes. Ondansetron will be diluted in 100mL 0.9% normal saline, and tariquidar will be diluted in 500mL D5W.</description>
    <arm_group_label>Ondansetron + Tariquidar</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron 16 mg with Placebo</intervention_name>
    <description>In randomized order, each participant will receive two IV infusions of ondansetron, 3 weeks apart; one with placebo (D5W), and one with tariquidar (4mg/kg dose in D5W) administered IV over 60 minutes. Ondansetron will be diluted in 100mL 0.9% normal saline, and tariquidar will be diluted in 500mL D5W.</description>
    <arm_group_label>Ondansetron + Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18-65;&#xD;
&#xD;
          2. Documented diagnosis of neuropathic pain due to damage or disease affecting the&#xD;
             peripheral nervous system;&#xD;
&#xD;
          3. At least Probable neuropathic pain grading1;&#xD;
&#xD;
          4. Pain duration &gt;3 months;&#xD;
&#xD;
          5. Average pain intensity ≥4 on 0-10 numerical rating scale (NRS).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Current pregnancy or lactation;&#xD;
&#xD;
          2. Moderate-severe kidney or liver dysfunction;&#xD;
&#xD;
          3. Active cardiac arrhythmias (non-sinus rhythm), Long QT syndrome, or QTc interval&#xD;
             &gt;450msec;&#xD;
&#xD;
          4. Congestive heart failure&#xD;
&#xD;
          5. Abnormal troponin values at screening visit;&#xD;
&#xD;
          6. Current treatment with MAO inhibitors, mirtazapine, SSRI antidepressants, or SNRI&#xD;
             medications duloxetine or venlafaxine;&#xD;
&#xD;
          7. Current treatment with tapentadol, tramadol, or fentanyl;&#xD;
&#xD;
          8. Current treatment with P-glycoprotein substrate drugs with narrow therapeutic window,&#xD;
             e.g. digoxin;&#xD;
&#xD;
          9. Current treatment with tricyclic antidepressant medications (e.g. amitriptyline,&#xD;
             desipramine, imipramine) at a dose &gt;25mg/day;&#xD;
&#xD;
         10. Ongoing use of any of the following medications with known effects on Pgp function:&#xD;
             carbamazepine, phenytoin, phenobarbital, cyclosporine, clarithromycin, erythromycin,&#xD;
             ritonavir, verapamil, rifampicin, St. John's wort;&#xD;
&#xD;
         11. Current treatment with QT-prolonging drugs, and drugs known to have a significant&#xD;
             interaction with ondansetron or other P-glycoprotein substrates (see section 2.3.3.);&#xD;
&#xD;
         12. Current treatment with anticoagulant drugs;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Simon Haroutounian, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karen Frey</last_name>
    <phone>314 454-5980</phone>
    <email>freyk@wustl.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Washington University School of Medicine/Barnes-Jewish Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Frey</last_name>
      <phone>314-454-5980</phone>
      <email>freyk@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Simon Haroutounian, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Finnerup NB, Haroutounian S, Kamerman P, Baron R, Bennett DLH, Bouhassira D, Cruccu G, Freeman R, Hansson P, Nurmikko T, Raja SN, Rice ASC, Serra J, Smith BH, Treede RD, Jensen TS. Neuropathic pain: an updated grading system for research and clinical practice. Pain. 2016 Aug;157(8):1599-1606. doi: 10.1097/j.pain.0000000000000492. Review.</citation>
    <PMID>27115670</PMID>
  </reference>
  <reference>
    <citation>Yawn BP, Wollan PC, Weingarten TN, Watson JC, Hooten WM, Melton LJ 3rd. The prevalence of neuropathic pain: clinical evaluation compared with screening tools in a community population. Pain Med. 2009 Apr;10(3):586-93. doi: 10.1111/j.1526-4637.2009.00588.x. Epub 2009 Mar 17. Erratum in: Pain Med. 2011 Aug;12(8):1294.</citation>
    <PMID>20849570</PMID>
  </reference>
  <reference>
    <citation>Smith BH, Torrance N. Epidemiology of neuropathic pain and its impact on quality of life. Curr Pain Headache Rep. 2012 Jun;16(3):191-8. doi: 10.1007/s11916-012-0256-0. Review.</citation>
    <PMID>22395856</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 21, 2020</study_first_submitted>
  <study_first_submitted_qc>October 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2020</study_first_posted>
  <last_update_submitted>September 23, 2021</last_update_submitted>
  <last_update_submitted_qc>September 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Washington University School of Medicine</investigator_affiliation>
    <investigator_full_name>simon.haroutounian</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ondansetron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

